Growth Hormone Pens – Growth Hormone In A Injection Pen

The aim of the study was to evaluate a multi-dose injection pen for subcutaneous administration of recombinant human growth hormone patients with somatotropic deficiency used a new generation of syringes for the administration of human growth hormone. The results of the questionnaire were assessed using a specially developed questionnaire A and it was found that the handle is easy to use, the new design of the cap with an additional cap covering the needle during injection avoids fear and discomfort during injection.

The reliability and ease of use for the treatment of patients with somatotropic insufficiency have been proven. The growth hormone pens proved to be convenient, its new design with an extra cap covering the needle during injection helps reduce the fear and discomfort during injection. The growth hormone pens are safe and simple to use and is recommended for the treatment of patients with somatotropic insufficiency.

The main goal of the development of somatotropic insufficiency in children is the normalization of the pace of physical development and the achievement of satisfactory indicators of final growth. For the treatment of pituitary dwarfism, human growth hormone (hGH) is used as replacement therapy. Since 1958, all countries have used exclusively preparations of growth hormone obtained by the extract, from the pituitary glands of human corpses However, further, starting in 1985, after the registration in a number of countries of a severe incurable degenerative disease of the central nervous system leading to death, the use of growth hormone extract preparations was officially banned.

Growth Hormone Pens

From that moment on, genetically engineered hGH preparations, completely identical to hGH, have been used to treat children with somatotropic insufficiency. Along with the transition to new hGH preparations, the doses and regimens of hGH administration were modified. improved injection systems for the introduction of recombinant hGH the use of growth hormone extract preparations was officially banned.

From this point on, genetically engineered hGH preparations, completely identical to hGH, have been used to treat children with somatotropic insufficiency. Along with the transition to new hGH preparations, the doses and modes of hGH administration were modified. improved injection systems for the introduction of recombinant hGH the use of growth hormone extract preparations was officially banned. From this point on, genetically engineered hGH preparations, completely identical to hGH, have been used to treat children with somatotropic insufficiency.

Along with the transition to new hGH preparations, the doses and modes of hGH administration were modified. improved injection systems for the introduction of recombinant hGH . It is known that in the early years of the use of hGH it was administered intramuscularly. In the early 1980s, it was shown that after subcutaneous injection of pituitary hGH, the increase and decrease in the concentration of the drug in the blood occurs more slowly than after intramuscular injection Subsequently, this was confirmed in studies with recombinant hGH.

In parallel with the transition to subcutaneous administration, the frequency of injections was also increased. Injection of hGH 2-3 times a week using conventional syringes did not meet the requirements of replacement therapy, since it led to a short-term super physiological increase in the level of hGH in the blood, followed by maintaining its low concentrations for several days … It has now been established that daily subcutaneous injection of hGH is approximately 25% more effective than intramuscular injection 3 times a week Also, the subcutaneous route of administration using short needles and less pain during injection compared to intramuscular administration was more preferable for patients.

At the same time, there remained a number of inconveniences associated with the need to prepare an hGH solution before each injection by the patient himself. This could lead to errors in the dosage of the drug, and also required additional time. Children with somatotropic insufficiency, due to the listed reasons, could not make injections on their own. In addition, there was a risk of infection with hepatitis, HIV, etc. Therefore, further developments were associated with the creation of special injection devices that make it possible to simplify daily injections of hGH, reduce the fear of injections, thus increasing patient compliance.

The growth hormone pens were such devices. They combined several positive properties: the use of a cartridge designed for several injections high dosage accuracy ease of use the presence of thin needles that significantly reduce pain the possibility of use by children for self-introduction Currently, there are a number of growth hormone pens with the above properties and differing in some technical features.

Add Comment